Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Mross

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
European Journal of Clinical Pharmacology|January 1, 1990
Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humansK Mross, U Mayer, K Hamm, et al.
Cancer Treatment Reviews|November 2, 1999
Current options in treatment of anthracycline-resistant breast cancerN Kröger, W Achterrath, S Hegewisch-Becker, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Tissue disposition and plasma concentrations of idarubicin after intravesical therapy in patients with bladder tumorsK Mross, K Hamm, W Schultze-Seemann, et al.
British Journal of Cancer|May 6, 1998
Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancerM Lehnert, K Mross, J Schueller, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patientsK Mross, U Mayer, T Langenbuch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1994
Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignanciesK Mross, P Bewermeier, W Krüger, et al.
Arzneimittel-Forschung|January 15, 2000
Phase II study with 5-fluorouracil and ginkgo biloba extract (GBE 761 ONC) in patients with pancreatic cancerB Hauns, B Häring, S Köhler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantationK Mross, J Reifke, P Bewermeier, et al.
Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift Fur Klinische Chemie Und Klinische Biochemie|December 1, 1986
Enolase isoenzymes as tumour markersK D Gerbitz, J Summer, I Schumacher, et al.
Onkologie|February 5, 2003
Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trialK Mross, B Häring, N Holländer, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
European Journal of Clinical Pharmacology|January 1, 1990
Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humansK Mross, U Mayer, K Hamm, et al.
Cancer Treatment Reviews|November 2, 1999
Current options in treatment of anthracycline-resistant breast cancerN Kröger, W Achterrath, S Hegewisch-Becker, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Tissue disposition and plasma concentrations of idarubicin after intravesical therapy in patients with bladder tumorsK Mross, K Hamm, W Schultze-Seemann, et al.
British Journal of Cancer|May 6, 1998
Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancerM Lehnert, K Mross, J Schueller, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patientsK Mross, U Mayer, T Langenbuch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1994
Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignanciesK Mross, P Bewermeier, W Krüger, et al.
Arzneimittel-Forschung|January 15, 2000
Phase II study with 5-fluorouracil and ginkgo biloba extract (GBE 761 ONC) in patients with pancreatic cancerB Hauns, B Häring, S Köhler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantationK Mross, J Reifke, P Bewermeier, et al.
Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift Fur Klinische Chemie Und Klinische Biochemie|December 1, 1986
Enolase isoenzymes as tumour markersK D Gerbitz, J Summer, I Schumacher, et al.
Onkologie|February 5, 2003
Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trialK Mross, B Häring, N Holländer, et al.
Pageof 7